|

Sentinel Lymph Node in Early-Stage Endometrium Cancer

RECRUITINGN/ASponsored by Istanbul University
Actively Recruiting
PhaseN/A
SponsorIstanbul University
Started2023-07-01
Est. completion2025-11
Eligibility
Age18 Years – 90 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06163963

Summary

The aim of this prospective study is to investigate whether the detection rate of sentinel lymph node (SLN) with double tracer injected at two different sites may be increased compared to the standard use of a single tracer with single site (cervix) injection in early-stage endometrial cancer.

Eligibility

Age: 18 Years – 90 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Must have preoperative histologic diagnosis of endometrial carcinoma
2. Must be in early stage ( stage1 and 2) endometrial carcinoma radiologically and clinically
3. Must have written informed consent

Exclusion Criteria:

1. Possible allergic reaction to commonly used drugs
2. Medical or surgical contraindications for comphrensive staging
3. Preoperative or intraoperative findings of advanced endometrial cancer

Conditions3

CancerEndometrial CancerSentinel Lymph Node

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.